<DOC>
	<DOCNO>NCT02625714</DOCNO>
	<brief_summary>A randomized , open-label , oral multiple dosing , two-part , two-way crossover clinical trial evaluate safety/tolerability pharmacokinetic profile SID142 healthy volunteer</brief_summary>
	<brief_title>Safety/Tolerability Pharmacokinetic Study SID142</brief_title>
	<detailed_description />
	<mesh_term>Arterial Occlusive Diseases</mesh_term>
	<criteria>1 . Healthy adult age 19 45 2 . Weights 50Kg , BMI 18.5 25.0 kg/m2 3 . Subject without congenital chronic disease require medical treatment pathological symptom opinion accord internal examination 4 . Subject acceptable laboratory result ECG result 5 . Negative result blood serum human chorionic gonadotropin [ hCG ] pregnancy test screen urine hCG pregnancy test prior administration female subject . In addition , least one condition correspond state Menopause ( menstruation least 2 year ) surgically sterile ( hysterectomy oophorectomy , tubal ligation method ) Male partner sterile ( confirm aspermia deferentectomy ) sole screen . Woman agree use proper method conception accurately continuously least 14 day first Investigational Product [ IP ] administration least 30days dosing . 6 . Male subject use contraception ( condom ) clinical trial maintain contraception agree donate sperm 28days last dosing . 7 . Subject give completely understood full explanation study , decide participate study sign write informed consent willingly . 1 . Female subject pregnant breastfeeding 2 . Person anaphylaxis IP component clinically significant medical history anaphylaxis drug 3 . Subject clinically significant medical history disease liver , kidney , nervous system , respiratory system , endocrine system , blood tumor , urinary system , cardiovascular system , musculoskeletal system psychiatric disorder others severe nephrotic disorder moderate severe hepatic disorder menstruation period aortocoronary stenosis complication disease predisposition bleed congestive heart failure arrhythmia diabetes mellitus glucose tolerance disorder 4 . Subject clinically significant finding electrocardiogram [ ECG ] result screen state QTc &gt; 450 m PR interval &gt; 200 msec QRS duration &gt; 120 msec 5 . Active liver disease inadequate laboratory result : AST [ aspartate aminotransferase ] , ALT [ alanine aminotransferase ] &gt; 1.5 x upper limit normal range 6 . At screening , subject clinically significant vital sign ( sit position blood pressure ) : Systolic blood pressure &gt; 140 mmHg &lt; 90 mmHg , diastolic pressure &gt; 90 mmHg &lt; 60 mmHg 7 . Hereditary galactose intolerance , Lapp lactase deficiency glucosegalactose malabsorption syndrome 8 . Subject presence gastroenteric disease history gastroenteric surgery influence drug absorption 9 . Subject seriously injure receive surgery show suspicious acute disease symptom within 4 week first administration . 10 . Consumption excessive alcohol continuously subject quit drinking within 3 day prior IP administration clinical trial period subject smoke 11 . A history take ETC drug [ Ethical drug ] , oriental medicine within 2 week OTC drug [ OvertheCounter drug ] within 1week prior first administration 12 . Participation another clinical trial previous 3 month first administration study 13 . Donation whole blood previous 2 month apheresis blood previous 1 month first administration 14 . The subject abnormal diet influence absorption , distribution , metabolism , excretion drug 15 . Consumption food influence drug metabolism caffeine within 48 hour first administration , subject quit consumption food whole study period . 16 . Positive result serum test ( HBsAg [ hepatitis B surface antigen ] , antiHCV Ab [ hepatitis C virus antibody ] , antiHIV Ab [ human immunodeficiency virus antibody ] , VDRL [ Venereal Disease Research Laboratory ] test )</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>